文献速递腹部介入MR

基于钆塞酸增强MRI功能肝脏影像评分预测经动脉化疗栓塞术后肝衰竭模型的建立与验证

Development and Validation of a Predictive Model for Liver Failure After Transarterial Chemoembolization Using Gadoxetic Acid-Enhanced MRI and Functional Liver Imaging Score.
PubMed 文献 · Acad Radiol · 2025-01-14

本研究纳入156例TACE术前4周内行钆塞酸增强MRI的患者,由两名放射科医师盲法评估肝胆期FLIS,构建预测TACE术后肝衰竭的列线图模型。术后肝衰竭发生率37.2%(58/156),多因素分析显示FLIS、门静脉血栓和INR为独立预测因子,模型AUC为0.759,特异度87.8%、敏感度56.9%,校准良好(χ²=7.101,P=0.526)。

要点

  • TACE术前4周内钆塞酸增强MRI肝胆期FLIS与术后肝衰竭独立相关,可作为术前风险评估指标。
  • FLIS预测模型AUC为0.759,特异度87.8%、敏感度56.9%,校准良好(χ²=7.101,P=0.526)。
  • 门静脉血栓和INR亦为TACE术后肝衰竭的独立预测因子。

核心结论

  • 基于FLIS的预测模型在预测TACE术后肝衰竭方面表现良好,可能作为实用的临床工具。

研究设计与样本

  • 预测模型开发与内部验证研究,共纳入156例TACE术前4周内行钆塞酸增强MRI的患者,由两名不知临床数据的放射科医师独立评估肝胆期FLIS,采用单因素和多因素logistic回归筛选独立预测因子并构建列线图,通过1000次bootstrap重采样进行内部验证。

关键影像表现/征象

  • FLIS在肝胆期图像上评估,用于定量评估肝功能,是TACE术后肝衰竭的独立预测因子。
  • 门静脉血栓和INR亦为TACE术后肝衰竭的独立预测因子。

诊断标准与关键数值

  • 模型预测TACE术后肝衰竭的AUC为0.759,特异度87.8%,敏感度56.9%。
  • 模型校准良好,Hosmer-Lemeshow检验χ²=7.101,P=0.526。
  • 术后肝衰竭发生率为37.2%(58/156)。

临床应用与阅片要点

  • 作者认为该FLIS预测模型可能作为实用的临床工具用于术前评估TACE术后肝衰竭风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: Post-transarterial chemoembolization liver failure (PTLF) is a potentially fatal complication of transarterial chemoembolization (TACE). Accurate preoperative prediction of PTLF is crucial for improving patient outcomes. This study aimed to develop and validate a prediction model based on the functional liver imaging score (FLIS) to assess the risk of PTLF.

MATERIALS AND METHODS: A total of 156 patients underwent Gadoxetic acid-enhanced MRI within four weeks before TACE. Two radiologists, unaware of the clinical data, independently assessed FLIS on hepatobiliary phase images to quantitatively assess liver function. Univariate and multivariate logistic regression analyses identified independent predictors of PTLF. A nomogram was developed and subjected to internal validation through bootstrap resampling of 1000 samples. The model's performance was conducted through the area under the curve (AUC), Hosmer-Lemeshow test, calibration curves, and decision curve analysis (DCA). P< 0.05 was considered statistically significant.

RESULTS: PTLF occurred in 37.2% of patients (58/156). Significant differences were observed in factors such as portal vein thrombosis, albumin, aspartate transaminase, international normalized ratio (INR), model for end-stage liver disease scoring, albumin-bilirubin score, and FLIS. Multivariate analysis showed FLIS, portal vein thrombosis, and INR as independent predictors. The model achieved an AUC of 0.759, with 87.8% specificity and 56.9% sensitivity, and demonstrated good calibration (χ² = 7.101, P=0.526). Calibration curves and DCA confirmed its clinical utility.

CONCLUSION: This FLIS-based prediction model performs well in predicting PTLF, potentially serving as a practical clinical tool.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Wu X, Wang Y, He Y, et al. Development and Validation of a Predictive Model for Liver Failure After Transarterial Chemoembolization Using Gadoxetic Acid-Enhanced MRI and Functional Liver Imaging Score. Acad Radiol. 2025. PMID: 39809606. doi:10.1016/j.acra.2024.12.068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。